SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-288513
Filing Date
2023-12-04
Accepted
2023-12-04 17:19:01
Documents
12
Period of Report
2023-12-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d618000d8k.htm   iXBRL 8-K 23769
  Complete submission text file 0001193125-23-288513.txt   141455

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ngm-20231201.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20231201_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20231201_pre.xml EX-101.PRE 10809
6 EXTRACTED XBRL INSTANCE DOCUMENT d618000d8k_htm.xml XML 3296
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 231464373
SIC: 2834 Pharmaceutical Preparations